Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Dec 18;22(1):154.
doi: 10.1186/s10194-021-01363-y.

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study

Fabrizio Vernieri  1 , Nicoletta Brunelli  2 , Roberta Messina  3 , Carmelina Maria Costa  2 , Bruno Colombo  3 , Paola Torelli  4 , Simone Quintana  4 , Sabina Cevoli  5 , Valentina Favoni  5 , Florindo d'Onofrio  6 , Gabriella Egeo  7 , Renata Rao  8 , Massimo Filippi  3 , Piero Barbanti #  7   9 , Claudia Altamura #  2
Affiliations
Observational Study

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study

Fabrizio Vernieri et al. J Headache Pain. .

Abstract

Background: Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway are effective and safe on migraine prevention. However, some drug agencies limited these treatments to one year due to their high costs. This study aimed at evaluating the effect of discontinuing mAbs anti-CGRP on monthly migraine days (MMDs) and disability in high-frequency episodic (HFEM) and chronic migraine (CM) patients.

Methods: This observational longitudinal cohort study was conducted at 10 Italian headache centres. Consecutive adult patients were followed-up for three months (F-UP1-3) after discontinuation of a one-year erenumab/galcanezumab treatment. The primary endpoint was the change in F-UP MMDs. Secondary endpoints included variation in pain intensity (Numerical Rating Scale, NRS), monthly acute medication intake (MAMI), and HIT-6 scores. We also assessed from F-UP1 to 3 the ≥50% response rate, relapse rate to CM, and recurrence of Medication Overuse (MO).

Results: We enrolled 154 patients (72.1% female, 48.2 ± 11.1 years, 107 CM, 47 HFEM); 91 were treated with erenumab, 63 with galcanezumab. From F-UP1 to F-UP3, MMDs, MAMI, NRS, and HIT-6 progressively increased but were still lower at F-UP3 than baseline (Friedman's analysis of rank, p < .001). In the F-UP1-3 visits, ≥50% response rate frequency did not differ significantly between CM and HFEM patients. However, the median reduction in response rate at F-UP3 was higher in HFEM (- 47.7% [25th, - 79.5; 75th,-17.0]) than in CM patients (- 25.5% [25th, - 47.1; 75th, - 3.3]; Mann-Whitney U test; p = .032). Of the 84 baseline CM patients who had reverted to episodic migraine, 28 (33.3%) relapsed to CM at F-UP1, 35 (41.7%) at F-UP2, 39 (46.4%) at F-UP3. Of the 64 baseline patients suffering of medication overuse headache ceasing MO, 15 (18.3%) relapsed to MO at F-UP1, 26 (31.6%) at F-UP2, and 30 (42.3%, 11 missing data) at F-UP3. Lower MMDs, MAMI, NRS, and HIT-6 and higher response rate in the last month of therapy characterized patients with ≥50% response rate at F-UP1 and F-UP3 (Mann-Whitney U test; consistently p < .01).

Conclusion: Migraine frequency and disability gradually increased after mAbs anti-CGRP interruption. Most patients did not relapse to MO or CM despite the increase in MMDs. Our data suggest to reconsider mAbs anti-CGRP discontinuation.

Keywords: Calcitonin gene-related peptide; Discontinuation; Migraine treatment; Monoclonal antibodies; Real-world.

PubMed Disclaimer

Conflict of interest statement

Fabrizio Vernieri received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan, Amgen, Angelini, Eli-Lilly, Lundbeck, Novartis, and Teva.

Roberta Messina received honoraria as speaker from Novartis, Eli Lilly, and Teva.

Bruno Colombo received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Novartis, Teva, Eli-Lilly Lusofarmaco Paola Torelli received travel grant, honoraria as a speaker, or for participating in advisory boards from Novartis, Teva, Eli Lilly, and Allergan.

Sabina Cevoli received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Novartis, Teva, Lilly, Allergan, Ibsa, Amgen and Lundbeck.

Valentina Favoni received honoraria as speaker or for participating in advisory boards from Ely-Lilly, Novartis and Teva.

Florindo d’Onofrio received grants and honoraria from Lilly, Teva, Novartis, Neopharmed.

Gabriella Egeo received travel grants and honoraria from Eli-Lilly, Novartis, New Penta and Ecupharma.

Renata Rao received honoraria for speaker panels from Teva, Lilly, Novartis.

Massimo Filippi is the Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and AriSLA (Fondazione Italiana di Ricerca per la SLA).

Piero Barbanti received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Alder, Allergan, Angelini, Bayer, ElectroCore, Eli-Lilly, GSK, Lusofarmaco, MSD, Novartis, Stx-Med, Teva, Visufarma, Zambon.

Claudia Altamura received travel grants and honoraria from Novartis, Eli Lilly, Lusofarmaco, Laborest, Allergan, Almirall.

Nicoletta Brunelli, Simone Quintana and Carmelina Maria Costa have nothing to disclose.

Figures

Fig. 1
Fig. 1
The frequencies of patients with ≥50% response rate at the last month of therapy with mAbs anti-CGRP pathway and at the three-months of discontinuation in CM and HFEM
Fig. 2
Fig. 2
The frequency of patients having at least 8 MMDs in the three months of mAbs anti-CGRP pathway discontinuation in CM and HFEM patients
Fig. 3
Fig. 3
The median value (95% CI bars) of MMDs percentual reduction in the last month of therapy in patients relapsing to < 50% response rate at F-UP1, F-UP2, F-UP3, and patients still responding at F-UP3 (Mann-Whitney U test)
Fig. 4
Fig. 4
The frequency of patients relapsing to CM (A) and MO (B) MMDs in the three months of mAbs anti-CGRP pathway discontinuation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Edvinsson L, Haanes KA, Warfvinge K, DiN K (2018) CGRP as the target of new migraine therapies - Successful translation from bench to clinic. Nat Rev Neurol 14:338–350 - PubMed
    1. Goadsby PJ, Uwe R, Hallstrom Y, Gregor B, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–2132. doi: 10.1056/NEJMoa1705848. - DOI - PubMed
    1. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434. doi: 10.1016/S1474-4422(17)30083-2. - DOI - PubMed
    1. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088. doi: 10.1001/jamaneurol.2018.1212. - DOI - PMC - PubMed
    1. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):E2211–E2221. doi: 10.1212/WNL.0000000000006640. - DOI - PMC - PubMed

Publication types

Substances